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ABSTRACT
Adenylosuccinate lyase (ADSL) is an enzyme acting in two pathways of purine 
nucleotide metabolism. Mutations in ADSL gene compromising the enzyme activity 
lead to an inherited metabolic disease with severe neurological involvement – ADSL 
deficiency. Three distinct clinical phenotypes can be distinguished based on onset and 
severity of symptoms. The pathogenic mechanisms leading to the development of 
symptoms and underlying the phenotypic heterogeneity are unclear. The main 
pathogenic effect is attributed to the toxic effects of accumulating succinylpurines 
(SAdo, SAICAr). Their concentrations in cerebrospinal fluid, particularly diverse 
SAdo/SAICAr ratio, do correspond with the phenotypic groups. It is hypothesized that 
it may result from a mutation specific and thus structural related non-parallel loss (or 
gain) of enzyme activity towards one of its substrates. The main goal of the thesis is to 
seek for biochemical and structural basis of the diverse SAdo/SAICAr ratios and thus 
explain a pathogenetic mechanism of ADSL deficiency.
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1. INTRODUCTION
Adenylosuccinate lyase (ADSL; EC 4.3.2.2.) is an enzyme acting in two pathways of 
purine nucleotide metabolism. It catalyses the conversion of succinylaminoimidazole 
carboxamide ribotide (SAICAR) into aminoimidazole carboxamide ribotide (AICAR) 
in the purine de novo synthesis pathway and the formation of adenosine monophosphate 
(AMP) from adenylosuccinate (SAMP) in the purine nucleotide cycle (Figure 1) [1, 2].
The native human ADSL has a homotetrameric structure with a subunit size of 
~50 kDa. Its three dimensional structure has not been determined yet. Based on 
crystallographic studies on ADSL from Thermotoga maritima [3] and Bacillus subtilis
[4] it is predicted that the protein homotetramer contains four active sites. Each of them 
is formed from regions of three different subunits.
The human ADSL gene consists of 13 exons [5], spans 23 kb on chromosome 22q13.1-
13.2 [6, 7] and is ubiquitously expressed in two alternatively spliced mRNA isoforms
[5].
Mutations in ADSL gene compromising the enzyme activity lead to an inherited 
metabolic disease with severe neurological involvement – ADSL deficiency (OMIM 
103050).
Biochemically the enzyme deficiency results into intercellular accumulation of both 
enzyme substrates SAICAR and SAMP. Accumulated substrates are subsequently 
dephosphorylated to SAICAriboside (SAICAr) and succinyladenosine (SAdo) 
respectively (Figure 1), and they are excreted and detectable in plasma, urine and 
cerebrospinal fluid (CSF). For their detection, several simple screening procedures have 
been developed [8].
To date, 60 patients with ADSL deficiency have been reported world-wide [9]. 
Affected patients manifest mostly within the first year of life with psychomotor 
retardation, seizures, hypotonia, growth retardation, muscular wasting and,
interestingly, also with a wide spectrum of behavioural changes such as autism,
aggressiveness or self-mutilation. Two distinct clinical phenotypes can be distinguished 
based on onset and severity of symptoms: 
i) Type I (severe form) presenting within the first months of life, encompassing 
the whole spectrum of disease symptoms and resulting in severe psychomotor 
retardation, developmental arrest, coma vigil and SAdo/SAICAr ratio in CSF 
≈ 1.
ii) Type II (moderate or mild form) presenting within the first years of life either 
with psychomotor retardation or hypotonia and SAdo/SAICAr ratio in CSF ≥ 
2.
The pathogenic mechanisms leading to the development of individual symptoms and 
underlying the phenotypic heterogeneity are unclear. No significant reduction in the 
rate of de-novo purine synthesis was found in fibroblasts of ADSL deficient patient
[10]. No abnormality in purine nucleotide concentrations was found in several tissues of 
ADSL deficient patients [11]. No differences in residual enzyme activities were found 
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to be associated with severity of the phenotype. The main pathogenic effect is therefore 
attributed to the toxic effects of accumulating succinylpurines [12]. 
Figure 1: Metabolic pathways of ADSL
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2. AIMS OF THE STUDY
The main pathogenic effect of ADSL deficiency is attributed to the toxic effects of 
accumulating succinylpurines [12]. Although, the absolute SAdo and SAICAr 
concentrations in body fluids do not correlate with severity of the phenotype, it has 
been found that diverse values of ratio between SAdo and SAICAr concentrations in 
cerebrospinal fluid (SAdo/SAICAr ratio) do correspond with the two main phenotypic 
groups [13, 14]. The mechanism(s) leading to the diverse ratios is (are) not clear. It is 
hypothesized that it may result from a mutation specific and thus structural related non-
parallel loss (or gain) of enzyme activity towards one of its substrates.
Relevant biochemical investigations answering this hypothesis are generally limited by 
the unavailability of one ADSL substrate SAICAR and a small number of patients and 
tissues. Another limiting factor is the unavailability of accumulating ADSL metabolites
(SAICAr and SAdo) for diagnostics and relevant in vitro and in vivo studies.
To explain pathogenic mechanisms of ADSL deficiency we have therefore decided to:
1. Develop methods for preparation and purification of ADSL substrates and 
their metabolites :
a) SAICAR
b) SAICAr and SAdo
2. Identify more patients and collect relevant clinical, biochemical and molecular 
data by means of world-wide provided complex diagnostics of ADSL 
deficiency based on screening, biochemical investigation of body fluids and 
tissues, mutation analysis and assessment of mutation pathogenity identified.
3. Study genotype-phenotype correlation:
a) Express recombinant mutated ADSL proteins (fmADSL) and to correlate
their catalytic properties with clinical and biochemical data (e.g. different 
SAdo/SAICAr ratio).
b) Correlate diverse SAdo/SAICAr ratios to biochemical and structural 
properties of corresponding mutant ADSL proteins:
- Create a database of all published patients with ADSL deficiency
- Express, purify and characterise recombinant mutant ADSL 
proteins selected according to their association with diverse 
SAdo/SAICAr ratios and different phenotypic groups
- Prepare, purify and crystallize human ADSL protein
- Use a human ADSL structure model in evaluation of structural 
alterations possessed by selected ADSL mutations.
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b)We created a database of all published patients with ADSL deficiency. We 
collected clinical, biochemical and molecular data of 57 patients from 16 countries 
(47 different mutations).
c)Now we are studying various SAdo/SAICAr ratios by other biochemical and 
structural studies (This project is supported by the Czech Science Foundation). In 
terms of the project:
o We focused to genotypes which correlate with various phenotype and 
SAdo/SAICAr ratios and prepared 21 appropriate mutated ADSL clones. The 
set of clones make us possible to characterized 17 patients with ADSL 
deficiency; 4 presented with neonatal, 6 with type I and 7 with type II 
phenotype.
o For complementation studies we introduced and optimized a system for 
purification of human recombinant wtADSL. This method we will use to study 
intersubunit complementation in human mutant recombinant ADSL proteins.
o We used the purification system for preparing human recombinant wtADSL in 
sufficient quantity and quality for crystallization, biochemical characterisation 
(analytical ultracentrifugation, circular dichroism) and antibody preparation.
6. ABBREVIATIONS
ADSL adenylosuccinate lyase
AICAR aminoimidazole carboxamide ribotide
AMP adenosine monophosphate
cDNA complementary DNA






fmADSL recombinant fusion mutated ADSL protein
fwtADSL recombinant fusion wt ADSL protein
HPLC High Performance Liquid Chromatography
IIMD the Institute of Inherited Metabolic Disorders
MBP Maltose Binding Protein
PEI-TLC polyethyleneimine-Thin Layer Chromatography
RT-PCR Reverse Transcriptase Polymerase Chain Reaction
SAdo succinyladenosine
SAICAr succinylaminoimidazole carboxamide riboside 
SAICAR succinylaminoimidazole carboxamide ribotide
SAMP adenylosuccinate
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis
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5. CONCLUSION
The summary of achieved results:
1. Preparation and purification of ADSL substrates
a)We prepared commercially unavailable ADSL substrate, SAICAR, in the amount 
and purity sufficient for enzymatic studies in ADSL deficient patients and for 
kinetic characterisation of mutated ADSL proteins. 
b)We developed methods for preparation and purification of SAdo and SAICAr, 
commercially unavailable dephosphorylated ADSL substrates, at a sufficient 
amount and purity for diagnostics and in vivo and in vitro toxic studies.  These 
methods we publicised [17]. These substrates were provided to clinical and 
scientific institutions in Padova (Italy), Barcelona (Spain), Amsterdam and 
Maastricht (the Netherlands).
2. Complex diagnostics of ADSL deficiency:
a)We introduced a system for complex diagnostics of ADSL deficiency based on 
screening, enzymatic examination of tissues, mutation analysis and testing the 
pathogenity of mutation, and offered the diagnostics in the international system 
GeneTests (http://www.genetests.org).
b)We diagnosed 22 patients in 18 families (8 Czech Republic, 7 Poland, 5 Germany, 
2 US) and obtained the worldwide unique collection of patients with ADSL-
deficiency. 
c)We characterised and published a prenatal and early neonatal form of ADSL 
deficiency [14]. This severe neonatal form of the disease seems to be associated
with particular genotypes and, since these patients may escape the diagnosis, may 
form a significant proportion of ADSL-deficiency. However if the diagnosis is 
known, prenatal diagnosis is possible and can be offered to affected families.
d)We performed prenatal examination of 2 embryos.
e)We collected a unique set of 9 fibroblast lines and 2 tissues sets from ADSL 
deficient patients.
f) We determined catalytic activity of ADSL in fibroblasts of 9 patients.
g)We cloned full length ADSL cDNA and introduced a system for expression, 
purification and a catalytic properties study of fusion recombinant human ADSL in 
E.coli. The methods were published [5].
h)We cloned 16 mutated ADSL cDNA. Then we expressed, purified and 
characterised relevant fusion recombinant ADSL proteins.
3. Study of genotype-phenotype correlation
a)We calculated a mean of homoallelic activities of fmADSL proteins by patients’
genotypes and correlated it with severity of phenotype e.g. different SAdo/SAICAr 
ratio. However, all the mutant enzymes studied, if active, displayed proportional 
decrease in activity towards both substrates, and therefore, no ground for the varied 
SAdo/SAICAr ratio was found [5].
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3. METHODS
3.1. PRODUCTION AND PURIFICATION OF SUBSTRATES
3.1.1. Production of substrates
SAICAR was generated in a reaction mixture (volume 1 ml, pH 7,5) containing 10 mM 
TRIS-HCl, 2 mM EDTA, 10 mM KCl, 20 mM fumaric acid, 2.6 mM AICAR and 10 
U/ml of human recombinant ADSL (fwtADSL, see 3.2.3). Reactions were run at 37°C 
for 5 hours. To monitor reaction direction, aliquots taken every 30 minutes were 
analyzed by HPLC. Reaction was stopped after 5 hours of incubation by boiling in 
water bath for 5 minutes.
SAICAr was generated in a reaction mixture (volume 50 ml) of identical composition 
as the mixture used for SAICAR preparation. The reaction was run for 5 hours, stopped 
by boiling and the mixture was supplemented with 1 mM MgCl2 and 10 U/ml of CIAP. 
Dephosphorylation was run at 37°C for 1 hour. Reaction was stopped by boiling and 
aliquot of the reaction mixture was analyzed by HPLC. 
SAdo was generated according to Van den Bergh et al. [15]: in reaction mixture 
(volume 50 ml, pH 8.0) containing 10 mM TRIS-HCl, 1 mM MgCl2, 2.6 mM SAMP 
and 10 U/ml CIAP. Reaction was run at 37°C for 1 hour and aliquot of the reaction 
mixture was analyzed by HPLC.
3.1.2. Purification of substrates
SAICAR: Reaction mixture (1 ml) containing SAICAR, AICAR and fumarate was 
concentrated by evaporation under stream of nitrogen at 40°C to final volume of 200 l.
Two 100 µl aliquots were applied on PEI-TLC plates (10 x 10 cm) and developed in 1 
M ammonium acetate [16]. The UV-light spots corresponding to SAICAR (RF 0.02) 
were scraped off and eluted with 1 ml of 1 M NH4OH. The PEI-cellulose was removed 
by centrifugation at 10 000 rpm for 30 minutes.  SAICAR was concentrated under 
stream of nitrogen at 40°C and its concentration was determined spectrophotometrically 
at 269 nm (UV-Vis Spectrometer Lambda 10, Perkin-Elmer, Beaconsfield, UK). The 
molar extinction coefficient 13.1 x 103 [15] was used for the calculation.
SAICAr: Reaction mixture (50 ml) containing SAICAr, AICAr and fumarate was 
applied on Dowex 50W column (150 x 10 mm). After washing the column with 200 ml 
of water, SAICAr and AICAr were eluted with 45 ml of 2 M ammonia. The pH of 
individual fractions was monitored. The alkalic fractions were collected and analyzed 
by HPLC. The fractions containing SAICAr and AICAr were pooled (30 ml) and 
ammonia was removed from the reaction mixture by stream of nitrogen at 40°C. 
Resulting mixture (pH 7) was applied on DEAE-Sephadex A50 column (160 x 10 mm). 
Column was washed with 100 ml of water and SAICAr was eluted with 100 ml of 0.01 
M HCl. The pH of collected fractions was monitored. Acidic fractions containing 
SAICAr were pooled (20 ml) and neutralized with 1 M NaOH. To remove the pink 
coloured reaction by-product, 0.2 g of active carbon were added to the product solution. 
Active carbon was removed by centrifugation and clear, colour-less supernatant was 
lyophilized. The final product was dissolved in water and its concentration was 
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determined by UV spectrophotometry at 269 nm. The molar extinction coefficient
13.1 x 103 [15] was used for the calculation.
SAdo: Reaction mixture (50 ml) was applied on DEAE-Sephadex A50 column (160 x 
10 mm). Column was washed with 50 ml of water and SAdo was eluted with 100 ml of 
0.01 M HCl. Acidic fractions were pooled (20 ml) and neutralized with 1 M NaOH. 
The final solution was lyophilized. SAdo was dissolved in water and its concentration 
was determined spectrophotometrically at 269 nm. The molar extinction coefficient 
19.2 x 103 [15] was used for the calculation.
HPLC analysis:
For HPLC analysis, Shimadzu 10A (HPLC) Liquid Chromatography System with PDA 
detector was used.
20 l aliquots of reaction mixture were injected onto the reverse phase Prontosil 120-3-
C18 AQ (200 x 4 mm id) 3-m HPLC column (Bischoff) and eluted by linear gradient
with acetonitril at a flow rate of 0.7 ml/min. Buffer contained 0.1 M KH2PO4 and 5 mM 
TBA.
UV absorbance of eluted compounds was monitored at 269 nm. The analyses were 
performed at ambient temperature (25  1°C). All buffers were filtered and degassed by 
passage through a 0.22 m filter under vacuum. 
3.2. METHODS FOR PATIENTS´ DIAGNOSIS
3.2.1. Biochemical methods
3.2.1.1. Screening
For screening of adenylosuccinate lyase deficiency we used a method based on thin-
layer chromatographic (TLC) detection of urinary SAICAr with Pauli's reagent (sodium 
diazobenzenesulphate).
For final diagnosis, we used a HPLC analysis of urinary/CSF SAdo and SAICAr on 
Shimadzu 10A Liquid Chromatography System with PDA detector. 10 l aliquots of 
diluted urine were injected onto the reverse phase Prontosil 120-3-C18 AQ (200 x 4 
mm id) 3-m HPLC column (Bischoff) and eluted by linear gradient acetate buffer at a 
flow rate of 0.7 ml/min. UV absorbance of eluted compounds was monitored at 269 nm. 
The analyses were performed at ambient temperature (25  1°C). All buffers were 
filtered and degassed by passage through a 0.22 m filter under vacuum. 
3.2.1.2. ADSL activities in cultured fibroblasts 
The ADSL activities were measured in lysate using the HPLC analysis of AMP and 
AICAR formed from both ADSL substrates, SAMP and SAICAR. The reactions were
run for 20 minutes at 37°C in 180 µl containing 10 mM Tris pH 8.2, 2 mM EDTA, 10 
mM KCl, 1 mM DTT, 4% glycerol and 32 µg protein. Substrate concentrations were 
0.14 and 0.09 mM for SAMP and SAICAR, respectively. SDS–PAGE analyses were 
performed according to standard procedure; protein concentrations were determined 
using the Bradford assay.
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mutation specific oligonucleotide primers. The constructs with the correct sequences 
were introduced into the E.coli strain DH5 F'IQ (Invitrogen).
In total, 21 mutant ADSL clones are available for intersubunit complementation 
experiments. These experiments enabled characterisation of 17 patients; 4 presented 
with neonatal, 6 with severe and 7 with mild phenotype. 
Tab. I: ADSL mutations, SAdo/SAICAr ratios and associated phenotypes in patients 
with ADSL deficiency
Mutation 1 Mutation 2 SAdo/SAICAr (CSF) Phenotype
R194C R396C nm neonatal
R426H Y114H 0,5 neonatal
Y114H E376D 0,6 neonatal
Y114H R396H 0,7 neonatal
E80D D87E 2,4 mild
M1V S448P 1,5 mild
R303C R303C 3,0 mild
R426H D430N 2,6 mild
Y114H R190Q 2,1 mild
R426H T450S 2,5 mild
R426H D268H mild
Y114H T242I 1,1* severe
R426H S23R 0,8* severe
P467R D268N nm severe
R194C D268N 1,0 severe
R426H R426H 1,4 severe
D215H I351T 1,4* severe
4.3.2.3. Preparation and purification of wtADSL protein
To obtain a sufficient amount of purified protein, wtADSL was prepared as a fusion 
protein with a maltose binding protein (MBP) by the method previously described [5]. 
ADSL-MBP protein was expressed in a pMAL-C2 system. After sonication and 
centrifugation, lysate was applied on amylose affinity columns (NEB). The fusion 
protein was bound to the amylose sorbent. After washing, fusion protein was cleaved on 
the column using factor Xa protease. Then ADSL was eluted from the column and 
SDS–PAGE analyses were performed. Purity of isolated ADSL was 95%. ADSL was 
produced in sufficient amount, and purity for crystallography, analytical 
ultracentrifugation, circular dichroism and antibody were prepared.
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compound heterozygotes and that probably two structurally different mutant enzymes 
are involved in tetrameric structure building in vivo. 
In the case of ADSL protein, such limitation may be partly overcome by experiments in 
which mutant proteins corresponding to individual genotypes are mixed together before 
further characterisation. In this process, called intersubunit complementation [4, 18-20], 
it is assumed that both mutant proteins recombine randomly and an array of 5 possible 
tetrameric structures with 64 different active sites may be formed. Hypothetically then, 
in a situation where structural and catalytic mutant proteins meet together, unique 
catalytic sites having disproportional activity towards one of the substrates may evolve 
and form the structural basis for diverse SAdo/SAICAr ratios. 
The main goal is to seek for biochemical and structural basis of the diverse 
SAdo/SAICAr ratios. 
The work is planned in the following steps:
1. Creation of a database of all published patients with ADSL deficiency
2. Selection of ADSL mutants associated with various phenotypes (e.g. diverse 
SAdo/SAICAr ratios) and its cloning
3. Preparation and purification of wt ADSL protein
4. Crystallization of human wt ADSL
5. Elucidation of human ADSL structure
6. Implementation and optimization of methods usable in characterization of 
intersubunit complementation
7. Expression, purification and characterization of mutant proteins through
complementation experiments
8. Modeling of selected ADSL mutations
This project is supported by the grant of the Czech Science Foundation number 
301/07/0600. To date, the first three planned work steps were carried out.
4.3.2.1. Database of all published patients with ADSL deficiency
We collected the unique set of 22 ADSL deficient patients. Because we needed a larger
set for study of all ADSL deficiency forms and their relation with genotype, we created 
a database of all published patients with ADSL deficiency. The database is in a 
Microsoft Access programe.
We collected clinical, biochemical and molecular data of 57 patients from 16 countries 
(47 different mutations). The set of patients showed that ADSL deficiency is 
multiethnic.
4.3.2.2. Selection of ADSL mutants associated with various phenotypes (e.g. different 
SAdo/SAICAr ratios) and its cloning
Fifteen cDNA constructs containing mutations found in 22 ADSL deficient patients 
were prepared, cloned and characterised in our previous studies (Tab. I, white fields) [5, 
14]. Additionally 6 mutations were selected according to their association with diverse 
SAdo/SAICAr ratio values (Tab. I, grey fields) and were cloned in pMAL-C2wtADSL 
clone using the GeneTailorTM Site – Directed Mutagenesis System (Invitrogen) with 
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3.2.2. Molecular biology methods
3.2.2.1. RT–PCR
Total RNA was isolated from peripheral blood lymphocytes, fibroblasts and skeletal 
muscle by the standard procedure. cDNA was reverse transcribed from total RNA using 
the SuperScript® First-Strand Synthesis System (Invitrogen) and oligo (dT) primer. 
ADSL cDNA was amplified in DNAengine Dyad termocycler (MJ Research) in a 
reaction volume of 25 µl containing 2.5U KlenTaq1 polymerase, 0.1 U DeepVent 
polymerase, 200 µM dNTPs, 0.15 µM primers and 1.5 mM MgCl2 under the following 
conditions: the initial denaturation at 94°C for 1 minute followed by 40 cycles of 
denaturation at 94°C for 10 seconds, primer annealing at 61°C for 5 seconds and 
extension at 72°C for 1 minute. Final chain elongation was performed at 72°C for 5
minutes.
3.2.2.2. DNA sequencing
cDNAs prepared by RT–PCR were purified using the NucleoSpin Extract II kit
(MACHEREY-NAGEL). Dideoxy cycle sequencing was performed in 7 µl containing 
150 fmol of template, 1 pmol of the Cy5 labelled primer, 100 µM dNTP (dNTP:ddNTP 
ratio = 120), 5 mM MgCl2 and AmpliTaq FS polymerase (PE Biosystems). Sequencing 
parameters were: initial denaturation (94°C for 2 minutes), 40 cycles of denaturation
(94°C for 5 seconds), annealing of primers at specific temperature for 25 seconds and 
extension (68°C for 50 seconds), followed by 10 cycles of denaturation (94°C for 5 
seconds) and extension at 68°C for 50 seconds. The samples were subsequently 
denatured in loading buffer (94°C for 3 minutes). Sequences were read on the
ALFExpress sequencer (Pharmacia).
3.2.2.3. Mutation analysis
To verify the nature of mutations and to be able to screen for individual mutations in 
affected families, we designed PCR–RFLP-based assays on genomic DNA. These 
assays were all based on the PCR-based introduction of either one or both, diagnostic 
and control, restriction enzyme recognition sequence sites. The genomic DNA for PCR 
analysis was isolated from blood samples (Qiagen).
3.2.2.4. Genomic DNA sequencing
The PCRs were carried out according to standard procedure. Genomic DNA (100 ng) 
was amplified in 25 µl containing 2.5 U KlenTaq1 polymerase, 0.1 U DeepVent 
polymerase, 200 µM dNTPs and 0.15 µM primers. Amplification products were gel 
purified using the NucleoSpin Extract II kit (MACHEREY-NAGEL). Purified 
fragments were sequenced using the T7 and Rp primers. The dideoxy cycle sequencing 
was performed in a 7 µl reaction containing 150 fmol of template, 1 pmol of the Cy5 
labelled primers, 100 µM dNTP (dNTP:ddNTP ratio = 120), 5 mM MgCl2 and 
AmpliTaq FS polymerase. The sequences were read on the ALFExpress sequencer.
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3.2.3. Expression and purification of ADSL recombinant proteins
3.2.3.1. Expression of ADSL protein in E. coli
The ADSL cDNA was prepared and cloned into the pCRII-TOPO vector (Invitrogen). 
The constructs of the correct sequence were used as templates for subsequent PCR 
amplification of ADSL cDNA using the 56S primer starting at the first ATG codon. 
PCR products were blunt end ligated into the pMAL-C2 vector (NEB). The constructs
with the correct sequences were introduced into the E.coli strain DH5 F'IQ (Invitrogen) 
for fusion protein production. Briefly, a 600 ml culture of transformed bacteria was 
grown at 37°C in a rich medium, 100 µg/ml ampicillin and 0.2% glucose, to a density 
A600 of 0.5. IPTG was added to a final concentration of 0.3 mM and incubation 
continued for an additional 3 hours. Bacteria were harvested by centrifugation at 3000 g
for 10 minutes. The pellets were resuspended in 10 mM Tris pH 8.2, 2 mM EDTA, 10 
mM KCl, 1 mM DTT, 4% glycerol buffer and sonicated four times for 15 seconds at 40 
W. Crude lysates were obtained by centrifugation at 8000 g for 30 minutes. Fusion 
proteins were isolated from crude lysate on amylose affinity columns (NEB). SDS–
PAGE analyses were performed according to standard procedure; protein 
concentrations were determined using the Bradford assay (Sigma).
3.2.3.2. Expression of mutated ADSL in E.coli
All mutated cDNAs were first cloned into the pCRII-TOPO vector (Invitrogen). 
Individual mutated alleles were sequenced and subsequently subcloned into the pMAL-
c2wtADSL construct using the appropriate set of restriction enzymes. PCR product was 
blunt end cloned into the pMAL-C2 vector as described above. Resulting clones were 
sequenced and introduced into E.coli strain DH5F'IQ. The protein expression 
experiments and enzyme activity measurements were performed in 20 ml cultures 
essentially as described above.
The ADSL activities were measured in isolated fusion protein using the HPLC analysis 
of AMP and AICAR formed from both ADSL substrates, SAMP and SAICAR. The 
reactions were run for 20 minutes at 37°C in 130 µl containing 10 mM Tris pH 7.5, 2 
mM EDTA, 10 mM KCl, 1 mM DTT, 4% glycerol and 18 µg protein. Substrate 
concentrations were 0.14 and 0.09 mM for SAMP and SAICAR, respectively.
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[19]. One of these histidines, His68, is spatially close to this conserved region. Based on 
the homology with the B. subtilis enzyme, it could be that the mutated histidine-114 
residue in this region interferes with a proper active site formation. Both mechanisms, 
the hampered monomer association and improper active site formation, or even a 
combination of both, can thus lead to the observed enzyme instability and inactivity. 
The diminished activity of the D268N and D268N mutants is easily explainable as the 
wild-type aspartic acid residue resides in the active enzyme site and is directly involved 
in the catalytic mechanism where it serves as an electron donor of the acidobasic 
cleavage [16]. The exchange of this acidic residue for the uncharged asparagine leads to 
active centre disruption but does not seem to interfere with the enzyme protein stability. 
The effect of the severe and mild mutations is very hard to explain using the 
experimental data. There is no doubt that the mutations severely compromising the 
enzymatic activity are disease causing. To be able to make such a statement for the 
group of mild mutations, temperature activation profiles and kinetic parameters of the 
expressed proteins were studied. Three mutants, A3V, R190Q and D430N, compared
with wild-type enzyme, showed modest changes in thermal stability and temperature 
dependence of ADSL activity suggesting the protein susceptibility to accelerated 
intracellular degradation.
4.3. GENOTYPE-PHENOTYPE CORRELATION
4.3.1. Determination of homoallelic activities and correlation with phenotype 
It is hypothesized that the mechanism(s) leading to the diverse ratios of SAdo/SAICAr 
may result from mutation specific and thus structural related non-parallel loss (or gain) 
of enzyme activity towards one of its substrates. However, all the mutant enzymes 
studied, if active, displayed a proportional decrease in activity towards both substrates,
and no ground for the varied SAdo/SAICAr ratio was therefore found [5]. 
During the studies, we identified and characterised a new neonatal form of ADSL 
deficiency [14] with a lack of spontaneous movements (“floppy infant”) and intractable 
seizures. ADSL deficiency may also have a prenatal manifestation with a lack of fetal 
heart rate variability, hypokinesia (with all its consequences up to arthrogryposis and 
pulmonary hypoplasia) and prenatal growth restriction. ADSL-deficiency has thus been
added to the differential diagnosis in this specific clinical context. This severe neonatal 
form of the disease seems to be associated with particular genotypes and, since these 
patients may escape the diagnosis, may form a significant proportion of ADSL 
deficiency. Once the diagnosis is known, however, prenatal diagnosis is possible and 
can be offered to affected families.
The results were published in journals Human Molecular Genetics in the year 2000 [5]
and Journal of Pediatrics in the year 2007 [14].
4.3.2. Characterisation of genotype - phenotype correlations 
In a previous study we calculated homoallelic activities of fmADSL proteins by 
patients’ genotypes, but no ground for the varied SAdo/SAICAr ratio was found. The 
main limitation of the previous experiments was that they were performed on single 




In case of positive biochemistry we determine ADSL cDNA and gDNA mutations. We 
check the results by a PCR-RFLP method. 
Most mutations found in ADSL-deficiency are missense mutations. The majority of 
them, except R426H, are private [9]. In our series of 22 patients, we identified 16 
mutations [5, 14]. The mutation c.340C>T (Y114H) we detected in 10 patients. To date, 
this mutation was not published; however, it may be a prevalence mutation [5, 14]. 
Based on positive mutation analysis, prenatal diagnoses of two fetuses were performed 
in a subsequent pregnancy on genomic DNA isolated from native chorionic villi and 
subsequently from cultured chorionic villi. The mutation analysis of the first fetus 
showed heterozygosity for the 340T>C allele inherited from the father and carried the 
wild type allele from the mother. Pregnancy was continued and a healthy boy was born. 
Urinary excretion of both SAdo and SAICAr was normal. He is now 2.5 years old with 
normal growth and development. The mutation analysis of the second fetus showed 
heterozygosity for the 340T>C and 1128G>C alleles inherited from both parents.  
Pregnancy was terminated.
4.2.2.2. Expression studies
Since the majority of ADSL mutations are private, we must prove its pathogenity. 
Accordingly we introduced a system based on characterisation of recombinant ADSL 
proteins expressed in E.coli.
We cloned mutations into a pMAL-c2 vector and transformed E.coli DH5F´IQ cells
for protein production. Corresponding mutant proteins were affinity purified on 
amylose binding resin and analyzed by SDS-PAGE.  Some protein had reduced 
expression. The possible explanation is a faster degradation by cells proteases. Then we 
measured activities of fmADSL using S-AMP and SAICAR as substrates. The proof of 
pathogenity is based on detection of reduced activities, altered catalytic properties (Km, 
Vmax) and/or altered enzyme thermal stabilityand temperature dependence properties. 
We cloned mutations of all patients’ diagnoses in IIMD except R337X (early stop 
codon). To see the functional effect of individual mutations we expressed 16 relevant 
amino acid sequence-altering alleles in E.coli and measured enzyme activities of the 
affinity-purified enzyme proteins with each ADSL substrate. According to the residual
activities, the mutant enzymes were divided into 3 groups: null mutations free of 
detectable enzymatic activity (Y114H, D268N and D268H); 7 mutations with enzyme 
activities substantially compromised (E376D, S23R, R194C, R396C, R396H, R426H 
and P467R); and 6 mild mutations with activities comparable to that of the wild-type 
enzyme (A3V, R190Q, D215H, T242I, I351T and D430N). We propose the following 
mechanisms to explain the causative effect in the category of null mutations. In the case 
of the Y114H mutation it may be the pronounced protein instability. The wild-type 
tyrosine-114 resides in a highly conserved region common to all members of the 
fumarase enzyme superfamily. Based on molecular modelling, this region was predicted 
to be essential for the Bacillus subtilis ADSL subunit assembly [19] . Furthermore, the 
active site of the B. subtilis ADSL is formed by histidine–histidine residues pairing
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4. RESULTS AND DISCUSSION
Screening for ADSL deficiency started in IIMD in 1993. Currently the diagnostic
system is based on screening HPLC analysis of body fluids, enzymatic examination of 
available tissues, mutation analysis and characterisation of mutant recombinant 
proteins. This unique diagnostic system is provided world-wide to interested parties 
through GeneTests database (http://www.genetests.org). We collected a worldwide 
unique cohort of 22 ADSL deficiency patients from 18 families (8 CR, 7 Poland, 5 
Germany and 2 USA). During their examinations, we identified a full-length coding 
sequence of ADSL cDNA, its isoform, 16 different mutations [5, 14] and characterised 
new a neonatal form of ADSL deficiency [14]. We also performed prenatal diagnoses
in two pregnancies, collected a set of 9 ADSL deficient fibroblast lines and secured 
several post-mortem tissues from 2 ADSL deficient patients.
The pathogenic mechanisms leading to the development of individual symptoms and 
underlying the phenotypic heterogeneity are unclear. The main pathogenic effect is 
therefore attributed to the toxic effects of accumulating succinylpurines [12]. Although, 
the absolute SAdo and SAICAr concentrations in body fluids do not correlate with 
severity of the phenotype, it has been found that diverse values of ratio between SAdo
and SAICAr concentrations in cerebrospinal fluid (SAdo/SAICAr ratio) do correspond 
with the two main phenotypic groups [13]. The mechanism(s) leading to the diverse 
ratios is (are) not clear. It is hypothesized that it may result from a mutation specific and 
thus structural related non-parallel loss (or gain) of enzyme activity towards one of its 
substrates. Relevant biochemical investigations answering this hypothesis are generally 
limited by the unavailability of one ADSL substrate SAICAR and by a small number of 
patients and tissues. Another limiting factor is the unavailability of cumulating ADSL 
metabolites (SAICAr and SAdo) for diagnostics and in vitro / in vivo toxic studies.
As an alternative approach, we therefore first cloned, expressed and purified fusion wt-
human ADSL (fwtADSL) and used this enzyme for SAICAR preparation [5, 17]. 
Afterwards we cloned, expressed, purified and characterised catalytic properties of 17 
fusion recombinant mutant ADSL proteins. We confirmed pathogenity of individual 
mutations, identified underlying structural and/or catalytic basis of the enzyme 
deficiency and found evidence that residual enzyme activity, calculated as a mean of 
homoallelic activities, correlates with the severity of the phenotype (e.g. different 
SAdo/SAICAr ratio). However, all the mutant enzymes studied, if active, displayed 
proportional decrease in activity towards both substrates, and no reason for the varied 
SAdo/SAICAr ratio was therefore found [5]. 
The main limitation of the experiments was that they were performed on single isolated 
proteins. This situation has not reflected the fact that the patients are mostly compound 
heterozygotes and that probably two structurally different mutant enzymes are involved 
in tetrameric structure building in vivo. 
In case of ADSL protein, such limitation may be partly overcome by experiments in 
which mutant proteins corresponding to individual genotypes are mixed together before 
further characterisation. In this process, which is called intersubunit complementation
[4, 18-20], it is assumed that both mutant proteins recombine randomly and an array of 
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5 possible tetrameric structures with 64 different active sites may be formed.
Hypothetically, in a situation where structural and catalytic mutant proteins meet 
together, unique catalytic sites having disproportional activity towards one of the 
substrates may evolve and form the structural basis for diverse SAdo/SAICAr ratios. 
The main goal is to seek for biochemical and structural basis of the diverse 
SAdo/SAICAr ratios and thus extend our previous studies on genotype – phenotype 
correlation in ADSL deficiency. 
4.1. PRODUCTION AND PURIFICATION OF ADSL SUBSTRATES
The strategies used for production of the commercially unavailable ADSL substrate 
SAICAR and of the dephosphorylated SAICAr and SAdo were based on the availability 
of fwtADSL [5] and CIAP. 
SAICAR
SAICAR was produced from fumarate and AICAR in a reaction catalyzed by 
recombinant human ADSL. The maximal SAICAR concentration in a reaction mixture 
was reached after 5 hours of incubation. After that period of time, concentration of 
SAICAR started to decrease due to a reverse reaction direction. Using purification on 
PEI-TLC plates we isolated 2 µmoles of SAICAR, which represents a production yield 
of about 76%.  HPLC analysis of the final product showed no presence of AICAR or 
fumarate.
SAICAr
SAICAr was produced by adding the CIAP to the SAICAR containing reaction mixture 
(50 ml) as described under the Experimental Section. Dephosphorylation of AICAR 
and SAICAR was 100%, so the final reaction mixture contained only AICAr, fumarate 
and SAICAr. SAICAr and AICAr were separated from fumarate by treatment with 
strong cation-exchange resin, and SAICAr was subsequently isolated from AICAr on a 
column filled with weak anion-exchange resin. During the latter purification step the 
preparative column became pink coloured. The pink coloured fraction co-eluted with 
SAICAr. To reveal the origin of pink colour fraction we analyzed eluent on HPLC with 
UV diode-array detection, but only a single peak corresponding to SAICAr was 
detected. Similar observations were reported by Van den Berghe [15]. The pink colour
probably arises from the reaction of the SAICAr amino group at weak acidic pH. Based 
on this assumption we neutralized the pink coloured SAICAr containing fraction and 
used active coal, which efficiently removed contaminating pink product. The amount of 
isolated SAICAr was 60 µmoles, which represents a production yield of about 46%. 
SAdo
SAdo was produced from the SAMP containing reaction mixture by adding the CIAP. 
Dephosphorylation of SAMP was almost 100%. The final reaction mixture also 
contained negligible amount of aglycon. After purification steps on the DEAE –
Sephadex column, the concentration of SAdo was estimated spectrophotometrically at 
269 nm. The amount of isolated SAdo was 60 µmoles, which represents a production 
yield of about 46%. 
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In summary, we modified reaction conditions previously described [15, 16] for 
SAICAR preparation and employed the full-length recombinant human ADSL enzyme
[5]. This approach resulted in shorter incubation time, more efficient substrate 
conversion and higher yield. Using described methods we prepared SAICAR in amount 
and purity sufficient for enzymatic studies in ADSL deficient patients and for kinetic 
characterisation of mutated ADSL proteins as described in our previous study [5]. 
SAICAr and SAdo, dephosphorylated forms of both ADSL substrates accumulate in 
body fluids of patients with ADSL deficiency. Various in vitro and in vivo experiments 
are therefore indicated to study eventual toxic effects of these compounds and their role 
in pathogenesis of severe neurological symptoms observed in patients. To prepare both 
compounds at sufficient amount and purity, we developed reaction schemes and 
purification procedures based on separations on cation- and anion-exchange resin 
columns, which are opposite to the preparative TLC method previously used, and are 
more efficient and easily scaleable. Described procedures are relatively simple and 
resulting products may be of use in a number of ADSL and purine de novo synthesis 
related studies.  
4.2. DIAGNOSIS OF ADSL DEFICIENCY
4.2.1. Biochemistry
Patients with ADSL deficiency are diagnosed at IIMD during a screening of 
unexplained developmental delay using TLC chromatography with Pauli reagent 
detection (SAICAR assay) [8]. We are examining urine of about 1000 patients every 
year. However, since TLC chromatography can cause false negative results, we use the 
HPLC analysis for general diagnosis showing accumulation of both SAICAr and SAdo. 
According to SAdo/SAICAr ratios we determine type I or type II ADSL deficiency.
Next, we determine catalytic activities of ADSL with both substrates in ADSL deficient 
fibroblasts. The activities are reduced.
Some patients examined had a low SAdo/SAICAr ratio, consistent with severe type I 
presentation. Interestingly, in available CSF samples, the SAdo/SAICAr ratio reached 
the lowest values we have had observed so far. Activities of ADSL in fibroblasts were 
also low (especially for SAICAR). They all shared severe muscular hypotonia 
necessitating mechanical ventilation, intractable seizures and early death. The majority 
of affected patients had impaired intrauterine growth, microcephaly and a lack in fetal 
heart rate variability. We thus characterized a new lethal neonatal variant of 
adenylosuccinate lyase (ADSL) deficiency.
In one patient, we did not detect SAdo and/or SAICAr, but we found its hydrolyzed 
products SAdenin and SAICA (ratio 1.6). Consecutively, we added SAdo and SAICAr
to urine. After several hours it was also hydrolyzed. We think that there is probably a 
new unpublished specific ribosidase present in patient’s L1 urine. Maybe this ribosidase 
degrades toxic SAdo and SAICAr. 
